“Adalimumab Efficacy in Hidradenitis Suppurativa Patients Is Sustained at Least Three Years With Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s128, https://doi.org/10.25251/skin.1.supp.127.